You are here

UTIs

After positive panel vote, Shionogi antibiotic scores US approval

After positive panel vote, Shionogi antibiotic scores US approval

Endpoints

Flag link:

Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies

Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies

Endpoints

Flag link:

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Endpoints

advisory panels

Flag link:

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

Endpoints

advisory panels

Flag link:

VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs

VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs

Pharmaceutical Business Review

clinical trials

complicated urinary tract infections

Flag link:

Merck's combination antibiotic scores FDA approval for urinary tract and abdominal infections

Merck's combination antibiotic scores FDA approval for urinary tract and abdominal infections

Endpoints

intra-abdominal infections

Flag link:

Nearing phase 3, resTORbio posts new data on infection drug

Nearing phase 3, resTORbio posts new data on infection drug

Fierce Biotech

respiratory infections

Flag link:

It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri

It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri

Fierce Pharma

Flag link:

Achaogen's stock rockets after positive UTI drug trial results

Achaogen's stock rockets after positive UTI drug trial results

Marketwatch

clinical trials

Flag link: